Antibody data
- Antibody Data
- Antigen structure
- References [15]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11511-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11511-1-AP, RRID:AB_2303802
- Product name
- TRIM44 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated TRIM44 antibody (Cat. #11511-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway.
TRIM44 mediated p62 deubiquitination enhances DNA damage repair by increasing nuclear FLNA and 53BP1 expression.
TRIM44 links the UPS to SQSTM1/p62-dependent aggrephagy and removing misfolded proteins.
MicroRNA-623 Inhibits Epithelial-Mesenchymal Transition to Attenuate Glioma Proliferation by Targeting TRIM44.
TRIM44 Promotes Colorectal Cancer Proliferation, Migration, and Invasion Through the Akt/mTOR Signaling Pathway.
TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.
TRIM44, a crucial target of miR-410, functions as a potential oncogene in osteosarcoma.
TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway.
Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma.
High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma.
TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.
Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway.
Novel function of Trim44 promotes an antiviral response by stabilizing VISA.
Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma.
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.
Chen L, Yi C, Li W, Tseng Y, Zhang J, Liu J
Journal of Cancer 2021;12(1):89-98
Journal of Cancer 2021;12(1):89-98
TRIM44 mediated p62 deubiquitination enhances DNA damage repair by increasing nuclear FLNA and 53BP1 expression.
Lyu L, Lin TC, McCarty N
Oncogene 2021 Aug;40(32):5116-5130
Oncogene 2021 Aug;40(32):5116-5130
TRIM44 links the UPS to SQSTM1/p62-dependent aggrephagy and removing misfolded proteins.
Lyu L, Chen Z, McCarty N
Autophagy 2021 Aug 12;:1-16
Autophagy 2021 Aug 12;:1-16
MicroRNA-623 Inhibits Epithelial-Mesenchymal Transition to Attenuate Glioma Proliferation by Targeting TRIM44.
Cui D, Wang K, Liu Y, Gao J, Cui J
OncoTargets and therapy 2020;13:9291-9303
OncoTargets and therapy 2020;13:9291-9303
TRIM44 Promotes Colorectal Cancer Proliferation, Migration, and Invasion Through the Akt/mTOR Signaling Pathway.
Li CG, Hu H, Yang XJ, Huang CQ, Yu XQ
OncoTargets and therapy 2019;12:10693-10701
OncoTargets and therapy 2019;12:10693-10701
TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.
Zhou X, Yang Y, Ma P, Wang N, Yang D, Tu Q, Sun B, Xiang T, Zhao X, Hou Z, Fang X
Journal of neuro-oncology 2019 Nov;145(2):211-222
Journal of neuro-oncology 2019 Nov;145(2):211-222
TRIM44, a crucial target of miR-410, functions as a potential oncogene in osteosarcoma.
Wang H, Fang ZL, Zhang GH, Ma X
OncoTargets and therapy 2018;11:3637-3647
OncoTargets and therapy 2018;11:3637-3647
TRIM44 promotes human esophageal cancer progression via the AKT/mTOR pathway.
Xiong D, Jin C, Ye X, Qiu B, Jianjun X, Zhu S, Xiang L, Wu H, Yongbing W
Cancer science 2018 Oct;109(10):3080-3092
Cancer science 2018 Oct;109(10):3080-3092
Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma.
Kawaguchi T, Komatsu S, Ichikawa D, Hirajima S, Nishimura Y, Konishi H, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017 Jun;39(6):1010428317700409
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017 Jun;39(6):1010428317700409
High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma.
Zhu X, Wu Y, Miao X, Li C, Yin H, Yang S, Lu X, Liu Y, Chen Y, Shen R, Chen X, He S
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 Nov;37(11):14615-14628
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 Nov;37(11):14615-14628
TRIM44 promotes proliferation and metastasis in non‑small cell lung cancer via mTOR signaling pathway.
Xing Y, Meng Q, Chen X, Zhao Y, Liu W, Hu J, Xue F, Wang X, Cai L
Oncotarget 2016 May 24;7(21):30479-91
Oncotarget 2016 May 24;7(21):30479-91
Trim44 facilitates the migration and invasion of human lung cancer cells via the NF-κB signaling pathway.
Luo Q, Lin H, Ye X, Huang J, Lu S, Xu L
International journal of clinical oncology 2015 Jun;20(3):508-17
International journal of clinical oncology 2015 Jun;20(3):508-17
Novel function of Trim44 promotes an antiviral response by stabilizing VISA.
Yang B, Wang J, Wang Y, Zhou H, Wu X, Tian Z, Sun B
Journal of immunology (Baltimore, Md. : 1950) 2013 Apr 1;190(7):3613-9
Journal of immunology (Baltimore, Md. : 1950) 2013 Apr 1;190(7):3613-9
Overexpression of TRIM44 contributes to malignant outcome in gastric carcinoma.
Kashimoto K, Komatsu S, Ichikawa D, Arita T, Konishi H, Nagata H, Takeshita H, Nishimura Y, Hirajima S, Kawaguchi T, Shiozaki A, Fujiwara H, Okamoto K, Tsuda H, Otsuji E
Cancer science 2012 Nov;103(11):2021-6
Cancer science 2012 Nov;103(11):2021-6
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.
Peters CJ, Rees JR, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, Zhang C, Save V, O'Donovan M, Rassl D, Alderson D, Caldas C, Fitzgerald RC, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group.
Gastroenterology 2010 Dec;139(6):1995-2004.e15
Gastroenterology 2010 Dec;139(6):1995-2004.e15
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- mouse testis tissue were subjected to SDS PAGE followed by western blot with 11511-1-AP(TRIM44 antibody) at dilution of 1:500
- Sample type
- tissue
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The TRIM44 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human TRIM44. This antibody recognizes human, mouse, rat antigen. The TRIM44 antibody has been validated for the following applications: ELISA, WB, IHC analysis.